Saturday, February 03, 2018 10:32:37 PM
. The French pharmaceutical firm Sanofi (NASDAQ: GCVRZ) is one of the companies playing the medical marijuana long-game. As a titan with an epic market cap of almost $124 billion, Sanofi is waiting around to scoop up the cannabis research and development companies once they hit that high. Their current research, involving a wide range of diseases and disorders, focuses on multiple sclerosis and other neurodegenerative diseases which can greatly benefit from cannabinoid-based medicines.
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM